JANEX-1-WHI-P131-DataSheet-生命科學試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEJANEX-1Cat. No.: HY-15508CAS No.: 202475-60-3Synonyms: WHI-P131; Jak3 inhibitor I分式: CHNO分量: 297.31作靶點: JAK作通路: Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month

2、溶解性數據體外實驗 DMSO : 3 mg/mL (10.09 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.3635 mL 16.8175 mL 33.6349 mL5 mM 0.6727 mL 3.3635 mL 6.7270 mL10 mM 0.3363 mL 1.6817 mL 3.3635 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內實驗 JANEX-1 is prepared in PB

3、S4.BIOLOGICAL ACTIVITY物活性 JANEX-1種有效的特異性 JAK3 抑制劑，Ki 為 2.3 M，IC50 為 78 M，JANEX-1 不抑制 JAK1 和JAK2。1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEIC50 & Target JAK378 M (IC50)體外研究 JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC50 of 78 M), does not inhibit JAK1 and JAK2,the ZAP/SYK famil

4、y tyrosine kinase SYK, the TEC family tyrosine kinase BTK, the SRC family tyrosinekinase LYN, or the receptor family tyrosine kinase insulin receptor kinase, even at concentrations as high as350 M. JANEX-1 induces apoptosis in JAK3-expressing human leukemia cell lines NALM-6 and LC1;19 butnot in mel

5、anoma (M24-MET) or squamous carcinoma (SQ20B) cells. WHI-P131 inhibits the clonogenicgrowth of JAK3-positive leukemia cell lines DAUDI, RAMOS, LC1;19, NALM-6, MOLT-3, and HL-60 (but notJAK3-negative BT-20 breast cancer, M24-MET melanoma, or SQ20B squamous carcinoma cell lines) in aconcentration-depe

6、ndent fashion. WHI-P131 inhibits clonogenic growth in a concentration-dependent fashionwith EC50s of 24.4 M for NALM-6 cells and 18.8 M for DAUDI cells. At 100 M, WHI-P131 inhibits the invitro colony formation by these leukemia cell lines by 99%. In contrast, JANEX-1 does not inhibit theclonogenic g

7、rowth of JAK3-negative M24-MET melanoma or SQ20B squamous carcinoma cell lines 1.體內研究 JANEX-1 is administered at doses ranging from 5 to 100 mg/kg. Evaluation of CPK activity revealed a dose-response curve with an effective dose 50 (ED50) value of 7.44 mg/kg. Mice receiving JANEX-1 displayedsignific

8、antly reduced CPK and LDH levels. In addition, the infarct size of JANEX-1-treated mice(30.162.79%) is significantly decreased when compared with I/R-operated mice (65.643.76%) 2. JANEX-1 (WHI-P131) is absorbed rapidly, and the time to reach the maximum plasma JANEX-1 concentration (tmax)is 24.71.7

9、min. JANEX-1 is rapidly eliminated with an elimination half-life of 45.65.5 min. Although thepredicted maximum plasma JANEX-1 concentration is 10.5 0.8 M, which is only half of the Cmax followingi.v. administration of the same bolus dose, the i.p. bioavailability is 94.6% and the systemic exposure l

10、evels(i.e., AUC) are very similar to those observed after i.v. injection (17.12.2 Mh versus 18.11.2 Mh) 3.PROTOCOLCell Assay 1 The following cell lines are used in various biological assays: NALM-6 (pre-B-ALL), LC1;19 (pre-B-ALL),DAUDI (B-ALL), RAMOS (B-ALL), MOLT-3 (T-cell ALL), HL60 (acute myeloge

11、nous leukemia), BT-20 (breastcancer), M24-MET (melanoma), SQ20B (squamous cell carcinoma), and PC3 (prostate cancer). These celllines are maintained in culture. Cells are seeded in six-well tissue culture plates at a density of 50104cells/well in a treatment medium containing various concentrations

12、of JANEX-1 (0.1, 0.2, 0.3, 0.4 and 0.5 nM)and incubated for 24-48 h at 37C in a humidified 5% CO2 atmosphere. Cells are examined for apoptoticchanges after treatment with JANEX-1 by the in situ TdT-mediated dUTP end-labeling assay using theApopTag apoptosis detection kit 1.MCE has not independently

13、confirmed the accuracy of these methods. They are for reference only.Animal Mice 2Administration 23 Pathogen-free 8-week-old male JAK3-/- (129S4-Jak3tm1Ljb) and C57BL/6 J mice are used. Mice are treatedwith JANEX-1 at a dose of 20 mg/kg (intraperitoneally) at 1 h before ischemia.Rats 3Male Lewis rat

14、s are divided into two experimental groups of five and are injected either i.v. via the dorsal veinof the penis or i.p. with a single 3.3 mg/kg bolus dose of JANEX-1. The rats are anesthetized by the2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEmethoxyfluran, and blood samples (0.2 mL) are collec

15、ted from rat tail vein before and at 5, 10, and 30 minand 1, 1.5, 2, 3, 4, and 6 h after i.v. injections or at 5, 10, 15, 30, and 45 min and 1, 1.5, 2, 3, 4, 5, and 7 hafter i.p. injections.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發(fā)表的科研獻 Sci

16、ence. 2017 Dec 1;358(6367). Autophagy. 2018;14(3):450-464. Patent. US20180263995A1.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Sudbeck EA, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. ClinCancer Res. 1999

17、Jun;5(6):1569-82.2. Oh YB, et al. Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice. Exp Mol Med.2013 May 17;45:e233. Uckun FM, et al. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 4-(4hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. Clin Cancer Res. 1999 Oct;5(10):2954-62.4. Xia F, et al. IL4 (interleukin 4) induces autophagy in B cell